Clinical response in patients with relapsed centroblastic centrocytic non-Hodgkin's lymphoma after treatment with anti-CD20 antibody IDEC C2B8 (MabThera)

Trial Profile

Clinical response in patients with relapsed centroblastic centrocytic non-Hodgkin's lymphoma after treatment with anti-CD20 antibody IDEC C2B8 (MabThera)

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2014

At a glance

  • Drugs Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 05 Dec 2013 New source identified and integrated: ClinicalTrials.gov record.
    • 23 Mar 2008 Status changed from in progress to completed, from Roche record.
    • 09 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top